Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant human MG53 protein - TRIM-edicine

Next Previous
Drug Profile

Recombinant human MG53 protein - TRIM-edicine

Alternative Names: MG53; Mitsugumin53; Recombinant Mitsugumin53; rhMG53; TRIM72

Latest Information Update: 28 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TRIM-edicine
  • Class Anti-ischaemics; Recombinant proteins
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ischaemia
  • No development reported Muscular dystrophies

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for preclinical development in Muscular-dystrophies in USA (Parenteral)
  • 03 Jan 2022 Preclinical development is still ongoing for Muscular dystrophies in USA (TRIM-edicine pipeline, January 2022)
  • 13 Nov 2021 Preclinical trials in Ischaemia in USA (Parenteral) before November 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top